Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study ID
NCT04910126
Phase
PHASE2
Status
Unknown

Conditions

  • Neoplasms, Connective and Soft Tissue
  • Sarcoma Metastatic
  • Sarcoma,Soft Tissue
  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg q3w up to 2 years
  • Adriamycin — DRUG
    adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles

Study Details

To evaluate the efficacy and safety of the combination of adriamycin and Camrelizumab in the first-line treatment of advanced soft tissue sarcoma

Key Dates

Start date
Nov 12, 2020
Status verified
May 2021
Primary completion
Jan 12, 2023
Completion
Nov 12, 2023

Study Design

Enrollment
84 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: experiment group
    adriamycin and Camrelizumab
  • Active Comparator: control group
    adriamycin

Primary Outcome Measure

PFS [ Time Frame: up to three years ]

Central Contacts

Related Studies